$PMN
ProMIS Neurosciences Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024004532 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.553M $1.650M $6.380M
YoY Change 6.33% -22.86% -12.52%
% of Gross Profit
Research & Development $2.124M $2.225M $7.883M
YoY Change -39.5% -65.15% -51.0%
% of Gross Profit
Depreciation & Amortization $0.00 $21.16K $321.00
YoY Change -100.0% 1265.16% -94.78%
% of Gross Profit
Operating Expenses $3.677M $3.875M $14.26M
YoY Change -26.03% -54.54% -39.0%
Operating Profit -$3.677M -$14.26M
YoY Change -26.03% -39.0%
Interest Expense $76.78K $371.0K $1.252M
YoY Change 583.05% -70.49% -68.79%
% of Operating Profit
Other Income/Expense, Net $41.56K -$76.80K $1.050M
YoY Change 269.78% -80.25%
Pretax Income -$3.635M -$3.580M -$13.21M
YoY Change -26.7% -50.72% -26.85%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.600M -$3.580M -$13.21M
YoY Change -28.0% -50.72% -26.85%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$1.07
Diluted Earnings Per Share -$0.19 -$0.18 -$1.07
COMMON SHARES
Basic Shares Outstanding 18.96M 18.89M 12.29M
Diluted Shares Outstanding 19.53M 12.29M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.529M $12.63M $12.63M
YoY Change -24.79% 113.83% 113.83%
Cash & Equivalents $2.497M $12.60M
Short-Term Investments $32.36K $32.36K $32.36K
Other Short-Term Assets $1.019M $910.0K $910.0K
YoY Change 1.48% -8.7% -8.7%
Inventory
Prepaid Expenses
Receivables $58.15K $58.15K
Other Receivables $20.49K $20.49K
Total Short-Term Assets $3.548M $13.62M $13.62M
YoY Change -19.51% 97.28% 97.28%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $3.548M $13.62M $13.62M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $3.548M $13.62M $13.62M
YoY Change -19.87% 96.68% 96.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.404M $7.843M $7.843M
YoY Change -79.91% 163.6% 163.6%
Accrued Expenses $1.242M $1.507M $1.507M
YoY Change -27.71% -56.18% -56.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.646M $9.350M $9.350M
YoY Change -69.61% 45.79% 45.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $825.3K $516.2K $516.2K
YoY Change -56.6% -72.24% -72.24%
Total Long-Term Liabilities $825.3K $516.2K $516.2K
YoY Change -56.6% -72.24% -72.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.646M $9.350M $9.350M
Total Long-Term Liabilities $825.3K $516.2K $516.2K
Total Liabilities $3.471M $9.866M $9.866M
YoY Change -67.28% 19.26% 19.26%
SHAREHOLDERS EQUITY
Retained Earnings -$97.10M -$93.47M
YoY Change 13.97% 16.46%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.10K $3.753M $3.753M
YoY Change
Total Liabilities & Shareholders Equity $3.548M $13.62M $13.62M
YoY Change -19.87% 96.68% 96.68%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$3.600M -$3.580M -$13.21M
YoY Change -28.0% -50.72% -26.85%
Depreciation, Depletion And Amortization $0.00 $21.16K $321.00
YoY Change -100.0% 1265.16% -94.78%
Cash From Operating Activities -$10.29M -$3.754M -$10.84M
YoY Change 301.75% -17.57% -36.34%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$1.350K -$1.350K
YoY Change
Cash From Investing Activities -$1.350K -$1.349K
YoY Change -3475.0% -31.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.3K -511.2K 17.75M
YoY Change -107.87% 173.28%
NET CHANGE
Cash From Operating Activities -10.29M -3.754M -10.84M
Cash From Investing Activities -1.350K -1.349K
Cash From Financing Activities 190.3K -511.2K 17.75M
Net Change In Cash -10.10M -4.266M 6.722M
YoY Change 297.06% -319.79% -160.74%
FREE CASH FLOW
Cash From Operating Activities -$10.29M -$3.754M -$10.84M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.754M -$10.84M
YoY Change -17.57% -36.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12292707
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7502609
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001374339
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8579284
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18885254
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.41
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41429
CY2023 dei Entity Registrant Name
EntityRegistrantName
PROMIS NEUROSCIENCES INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A6
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0647155
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 200, 1920 Yonge Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Toronto
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
ON
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
M4S 3E2
CY2023 dei City Area Code
CityAreaCode
416
CY2023 dei Local Phone Number
LocalPhoneNumber
847-6898
CY2023 dei Security12b Title
Security12bTitle
Common Shares, No Par Value per Share
CY2023 dei Trading Symbol
TradingSymbol
PMN
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Public Float
EntityPublicFloat
29700000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18961116
CY2023 dei Auditor Firm
AuditorFirmId
23
CY2023 dei Auditor Name
AuditorName
Baker Tilly US, LLP
CY2023 dei Auditor Location
AuditorLocation
Tewksbury, Massachusetts
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12598146
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5875796
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
32358
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
31009
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
988641
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
996682
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13619145
CY2022Q4 us-gaap Assets Current
AssetsCurrent
6903487
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20838
CY2023Q4 us-gaap Assets
Assets
13619145
CY2022Q4 us-gaap Assets
Assets
6924646
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7843136
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2975398
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1506526
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3437646
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9349662
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6413044
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
422002
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
94185
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
1859374
CY2023Q4 us-gaap Liabilities
Liabilities
9865849
CY2022Q4 us-gaap Liabilities
Liabilities
8272418
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18885254
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8579284
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
97590426
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79101061
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-371184
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-195369
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93465946
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80253464
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3753296
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347772
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13619145
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6924646
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7883165
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16087168
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6379568
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7292744
CY2023 us-gaap Operating Expenses
OperatingExpenses
14262733
CY2022 us-gaap Operating Expenses
OperatingExpenses
23379912
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-14262733
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-23379912
CY2023 pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
866738
CY2022 pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
4176767
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
201390
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
282064
CY2022 pmn Gains Losses On Extinguishment Of Debt And Derivative Liability
GainsLossesOnExtinguishmentOfDebtAndDerivativeLiability
1307421
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
384903
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
115525
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1050251
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5317649
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-13212482
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18062263
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7450
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13212482
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18069713
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.41
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12292707
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7502609
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5660058
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
487630
CY2022 pmn Stock Issued During Period Value Conversion Of Convertible Debt And Derivative Liability
StockIssuedDuringPeriodValueConversionOfConvertibleDebtAndDerivativeLiability
5600000
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
977624
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4974253
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7450
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18062263
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347772
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271542
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2738558
CY2023 pmn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3600
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1287400
CY2023 pmn Adjustments To Additional Paid In Capital Warrant Reclassified Due To Change In Functional Currency
AdjustmentsToAdditionalPaidInCapitalWarrantReclassifiedDueToChangeInFunctionalCurrency
-396375
CY2023 pmn Apic Share Based Payment Arrangement Equity Classified Stock Options To Share Based Compensation Liability Due To Change In Functional Currency
ApicShareBasedPaymentArrangementEquityClassifiedStockOptionsToShareBasedCompensationLiabilityDueToChangeInFunctionalCurrency
1435912
CY2023 pmn Apic Share Based Payment Arrangement Remeasurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions
1013910
CY2023 pmn Foreign Currency Translation
ForeignCurrencyTranslation
-175815
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-13212482
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3753296
CY2023 us-gaap Profit Loss
ProfitLoss
-13212482
CY2022 us-gaap Profit Loss
ProfitLoss
-18062263
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
271542
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
487630
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1817
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-305407
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
2550877
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-866738
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1561987
CY2023 us-gaap Depreciation
Depreciation
321
CY2022 us-gaap Depreciation
Depreciation
6144
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
241854
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20838
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5072
CY2022 pmn Gains Losses On Extinguishment Of Debt And Derivative Liability
GainsLossesOnExtinguishmentOfDebtAndDerivativeLiability
1307421
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
187321
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
318747
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4963218
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2675693
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1831237
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3045612
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10843676
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17033883
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
32358
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
31009
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
31009
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
31009
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1981
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1349
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1981
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4974253
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1520401
CY2023 pmn Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
17745200
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3600
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17748800
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6494654
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-181425
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-526899
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6722350
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11068109
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5875796
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16943905
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12598146
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5875796
CY2022 pmn Conversion Of Convertible Debt And Derivative Liability To Series1 Convertible Preferred Shares
ConversionOfConvertibleDebtAndDerivativeLiabilityToSeries1ConvertiblePreferredShares
5600000
CY2023 pmn Deferred Issuance Cost Included In Accounts Payable And Accrued Liabilities
DeferredIssuanceCostIncludedInAccountsPayableAndAccruedLiabilities
195362
CY2023 pmn Issuance Of Compensation Warrants In Consideration Of Issuance Costs
IssuanceOfCompensationWarrantsInConsiderationOfIssuanceCosts
466658
CY2022 pmn Issuance Of Compensation Warrants In Consideration Of Issuance Costs
IssuanceOfCompensationWarrantsInConsiderationOfIssuanceCosts
317000
CY2023 pmn Reclassification Of Warrants From Equity To Liability
ReclassificationOfWarrantsFromEquityToLiability
-396375
CY2023 pmn Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
1287400
CY2023 pmn Decrease In Additional Paid In Capital For Share Based Compensation Liability
DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability
681308
CY2022 us-gaap Interest Paid Net
InterestPaidNet
87069
CY2023 pmn Other Interest Paid
OtherInterestPaid
201390
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-13212482
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93465946
CY2022Q2 pmn Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
60
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the valuation of warrant liabilities and embedded derivative liabilities. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements.</p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees 100% of the original amount invested. Management believes that these financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these high-quality financial institutions. As of December 31, 2023, the Company has not experienced any losses on its cash or short-term investments as a result of credit risk.</p>
CY2023 pmn Percentage Of Original Amount Invested
PercentageOfOriginalAmountInvested
1
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
CY2023 pmn General And Administration Expenses On Abandoned Offering
GeneralAndAdministrationExpensesOnAbandonedOffering
800000
CY2023Q4 pmn Deferred Financing Cost Assets
DeferredFinancingCostAssets
200000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 pmn Fair Value Assets Liabilities Level2 Transfers Amount
FairValueAssetsLiabilitiesLevel2TransfersAmount
0
CY2023Q4 pmn Fair Value Assets Liabilities Level2 Transfers Amount
FairValueAssetsLiabilitiesLevel2TransfersAmount
0
CY2022Q4 pmn Fair Value Assets Liabilities Level1 Transfers Amount
FairValueAssetsLiabilitiesLevel1TransfersAmount
0
CY2023Q4 pmn Fair Value Assets Liabilities Level1 Transfers Amount
FairValueAssetsLiabilitiesLevel1TransfersAmount
0
CY2023Q4 pmn Prepaid Upfront Research Payments Current
PrepaidUpfrontResearchPaymentsCurrent
146851
CY2022Q4 pmn Prepaid Upfront Research Payments Current
PrepaidUpfrontResearchPaymentsCurrent
346015
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
20485
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
71626
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
58152
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
482297
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
471088
CY2023Q4 pmn Prepaid Dues And Subscriptions Current
PrepaidDuesAndSubscriptionsCurrent
12529
CY2022Q4 pmn Prepaid Dues And Subscriptions Current
PrepaidDuesAndSubscriptionsCurrent
7926
CY2023Q4 pmn Prepaid Consultants Current
PrepaidConsultantsCurrent
21535
CY2022Q4 pmn Prepaid Consultants Current
PrepaidConsultantsCurrent
56797
CY2023Q4 pmn Prepaid License Fee Current
PrepaidLicenseFeeCurrent
30472
CY2022Q4 pmn Prepaid License Fee Current
PrepaidLicenseFeeCurrent
25700
CY2023Q4 us-gaap Deposit Assets
DepositAssets
14161
CY2022Q4 us-gaap Deposit Assets
DepositAssets
12907
CY2023Q4 pmn Deferred Financing Cost Assets
DeferredFinancingCostAssets
195632
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6527
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4623
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
988641
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
996682
CY2023Q4 pmn Accrued Legal Fees Current
AccruedLegalFeesCurrent
-66254
CY2023Q4 pmn Deferred Financing Costs
DeferredFinancingCosts
99883
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
101528
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
73970
CY2023Q4 pmn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
-691908
CY2022Q4 pmn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
-3185346
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
518704
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28249
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178330
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1506526
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3437646
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2741058
CY2022Q4 pmn Common Stock Fair Value Per Share On Conversion Date
CommonStockFairValuePerShareOnConversionDate
0.08
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18885254
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18885254
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8579284
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8579284
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13595987
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1873622
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
898262
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1043025
CY2023Q4 pmn Deferred Share Units Outstanding
DeferredShareUnitsOutstanding
1061
CY2022Q4 pmn Deferred Share Units Outstanding
DeferredShareUnitsOutstanding
1061
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
471843
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
396080
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16133820
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4480455
CY2023 pmn Number Of Votes Per Common Share
NumberOfVotesPerCommonShare
1
CY2022Q4 pmn Payments Of Warrants Issuance Costs
PaymentsOfWarrantsIssuanceCosts
249733
CY2023Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
9772464
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13595987
CY2023Q3 pmn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
1768515
CY2023Q3 pmn Apic Share Based Payment Arrangement Equity Classified Stock Options To Share Based Compensation Liability Due To Change In Functional Currency
ApicShareBasedPaymentArrangementEquityClassifiedStockOptionsToShareBasedCompensationLiabilityDueToChangeInFunctionalCurrency
-1435912
CY2023Q3 pmn Shareoptionsreclassificationtoliabilitiesduetochangeinfunctionalcurrencysharebasedcompensationexpense
Shareoptionsreclassificationtoliabilitiesduetochangeinfunctionalcurrencysharebasedcompensationexpense
332602
CY2023 pmn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
442002
CY2023Q4 pmn Deferred Tax Assets Tax Value Of Technology Rights And Property And Equipment In Excess Of Accounting Basis
DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis
221000
CY2022Q4 pmn Deferred Tax Assets Tax Value Of Technology Rights And Property And Equipment In Excess Of Accounting Basis
DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis
250000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1019000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
656000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27725000
CY2023 us-gaap Increase Decrease In Fair Value Adjustments On Assets And Liabilities Carried At Fair Value Under Fair Value Option
IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
1013910
CY2023 pmn Shareoptionsreclassificationtoliabilitiesduetochangeinfunctionalcurrencysharebasedcompensationexpense
Shareoptionsreclassificationtoliabilitiesduetochangeinfunctionalcurrencysharebasedcompensationexpense
332602
CY2023 pmn Apic Share Based Payment Arrangement Remeasurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions
681308
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.40
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2231293
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.54
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.98
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.60
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1183860
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.10
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.76
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.58
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.46
CY2023Q4 us-gaap Share Price
SharePrice
1.30
CY2023Q3 us-gaap Share Price
SharePrice
2.54
CY2023 pmn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
105790
CY2023Q4 us-gaap Share Price
SharePrice
1.53
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
271542
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
487630
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
266701
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4841
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
100948
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M18D
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21151000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17614000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3246000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3346000
CY2023Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
2088000
CY2022Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
2152000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24018000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27725000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24018000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
12248000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3559000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4887000
CY2023 pmn Effective Income Tax Rate Reconciliation Permanent Differences Amount
EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount
-157000
CY2022 pmn Effective Income Tax Rate Reconciliation Permanent Differences Amount
EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount
-1164000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-731000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-271000
CY2023 pmn Effective Income Tax Rate Reconciliation Unrecognized Benefit Of Current Year Tax Losses Amount
EffectiveIncomeTaxRateReconciliationUnrecognizedBenefitOfCurrentYearTaxLossesAmount
4447000
CY2022 pmn Effective Income Tax Rate Reconciliation Unrecognized Benefit Of Current Year Tax Losses Amount
EffectiveIncomeTaxRateReconciliationUnrecognizedBenefitOfCurrentYearTaxLossesAmount
6322000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 pmn Cash Payments Related Party
CashPaymentsRelatedParty
588136
CY2022 pmn Cash Payments Related Party
CashPaymentsRelatedParty
461516
CY2023Q4 pmn Collaborative Arrangement Accruals For Royalty Payments
CollaborativeArrangementAccrualsForRoyaltyPayments
0
CY2016Q2 pmn Related Party Transaction Term Of Agreement
RelatedPartyTransactionTermOfAgreement
P3Y
CY2022 pmn Annual License Payment
AnnualLicensePayment
25000
CY2023 pmn Annual License Payment
AnnualLicensePayment
25000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
13212482
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
18062263
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12292707
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7502609
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.41
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15136252
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4084375
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-004532-index-headers.html Edgar Link pending
0001558370-24-004532-index.html Edgar Link pending
0001558370-24-004532.txt Edgar Link pending
0001558370-24-004532-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmn-20231231.xsd Edgar Link pending
pmn-20231231x10k.htm Edgar Link pending
pmn-20231231x10k001.jpg Edgar Link pending
pmn-20231231x10k003.jpg Edgar Link pending
pmn-20231231x10k005.jpg Edgar Link pending
pmn-20231231x10k006.jpg Edgar Link pending
pmn-20231231x10k007.jpg Edgar Link pending
pmn-20231231x10k008.jpg Edgar Link pending
pmn-20231231x10k009.jpg Edgar Link pending
pmn-20231231x10k010.jpg Edgar Link pending
pmn-20231231x10k011.jpg Edgar Link pending
pmn-20231231x10k012.jpg Edgar Link pending
pmn-20231231x10k013.jpg Edgar Link pending
pmn-20231231x10k014.jpg Edgar Link pending
pmn-20231231x10k015.jpg Edgar Link pending
pmn-20231231x10k016.jpg Edgar Link pending
pmn-20231231x10k017.jpg Edgar Link pending
pmn-20231231x10k018.jpg Edgar Link pending
pmn-20231231x10k019.jpg Edgar Link pending
pmn-20231231x10k020.jpg Edgar Link pending
pmn-20231231x10k021.jpg Edgar Link pending
pmn-20231231xex21d1.htm Edgar Link pending
pmn-20231231xex23d1.htm Edgar Link pending
pmn-20231231xex31d1.htm Edgar Link pending
pmn-20231231xex31d2.htm Edgar Link pending
pmn-20231231xex32.htm Edgar Link pending
pmn-20231231xex97d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pmn-20231231_def.xml Edgar Link unprocessable
pmn-20231231x10k_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pmn-20231231_cal.xml Edgar Link unprocessable
pmn-20231231_lab.xml Edgar Link unprocessable
pmn-20231231_pre.xml Edgar Link unprocessable